← PG forward model

PG · Forward model · Health Care · Jejurikar case

What has to happen in Health Care

Model as of

This page changes Health Care inside the complete PG model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.

PG forward model
Horizon
Consolidated fair value $136.65 all other verticals held in this portfolio case
Final-quarter revenue $3.05B 13% of company revenue
Explicit segment contribution $13.23B EBITDA less segment capex, before corporate items

The new CEO's own framing, taken literally. Shailesh Jejurikar took over in January 2026 and told the July call that P&G would accelerate growth from semester to semester, with the cost headwind anniversaried by the back half. This case leaves the first half of fiscal 2027 exactly on the trailing run-rate while the $1bn after-tax cost vintage sits in it, then steps the five operating segments up 2.56% in level from the January-March 2027 quarter onward - Corporate is left alone, because an overhead residual should not be stepped up with the operating lines. The second half then prints $43.71bn, 3.0% above the same half of fiscal 2026, which is the top of the guided range; the year lands at $88.52bn, +1.70%. What this case does NOT reach is the guidance midpoint of about $88.77bn: a first half held at the trailing rate is too big a hole for one good half to fill, and getting there would need the second half to run above the top of the guided range. Fair value is $136.65, still 5.8% below the price, because a shaped year at 15x is worth about $3.60 a share more than a flat one, not $12.

Health Care

Basis quarter$2.76B
Final quarter$3.05B
Implied CAGR+2%
Final revenue mix13%

Oral Care (Crest, Oral-B) and Personal Health Care (Vicks, Metamucil, Pepto-Bismol). The most seasonal line in the company.

Last four quarters
2025 Q3 $3.22B Reported
2025 Q4 $3.41B Reported
2026 Q1 $3.07B Reported
2026 Q2 $2.76B Reported
Oral Care (Toothbrushes, Toothpastes, Other Oral Care)Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements)
Sequential growth +0.4%/qtr decaying toward +0.4% 0.38%/qtr: eight-quarter compound growth of deseasonalised Health Care net sales, after removing the flu shape.
Health Care

Latest: $3.05B (2031Q2E)

Period Value
2021Q3 $2.68B
2021Q4 $2.98B
2022Q1 $2.66B
2022Q2 $2.51B
2022Q3 $2.76B
2022Q4 $3.05B
2023Q1 $2.83B
2023Q2 $2.59B
2023Q3 $3.07B
2023Q4 $3.17B
2024Q1 $2.87B
2024Q2 $2.67B
2024Q3 $3.15B
2024Q4 $3.25B
2025Q1 $2.88B
2025Q2 $2.72B
2025Q3 $3.22B
2025Q4 $3.41B
2026Q1 $3.07B
2026Q2 $2.76B
2026Q3E $3.18B
2026Q4E $3.35B
2027Q1E $3.10B
2027Q2E $2.87B
2027Q3E $3.32B
2027Q4E $3.49B
2028Q1E $3.14B
2028Q2E $2.92B
2028Q3E $3.37B
2028Q4E $3.55B
2029Q1E $3.19B
2029Q2E $2.96B
2029Q3E $3.42B
2029Q4E $3.60B
2030Q1E $3.24B
2030Q2E $3.01B
2030Q3E $3.47B
2030Q4E $3.66B
2031Q1E $3.29B
2031Q2E $3.05B

Assumptions & reasoning

  • Segment identity, not an apportionment. Sixteen quarters are read from filed segment tables; the four April-June quarters are derived as fiscal-year total less the nine-month column and are marked estimated. No dollar split between Oral Care and Personal Health Care is disclosed and none is manufactured.
  • The four seasonal factors are the largest and most economically legible shape in the company: October-December peaks at 1.087 and April-June troughs at 0.901, which is the cold, flu and respiratory season in Personal Health Care. The 10-K names Personal Health Care as a seasonal component while saying no reportable segment is highly seasonal, and both statements are consistent with an 18.7-point amplitude on a 2.5-point window-to-window spread.
  • The 28.92% EBITDA margin is fiscal 2026: (earnings before income taxes $3,163m + depreciation and amortisation $439m) / net sales $12,456m. Health Care organic sales fell 1% in the June quarter, with Oral Care down mid single digits on volume declines in North America and Greater China.
PG model map

Explore another vertical